Trial Profile
Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2011
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 08 Mar 2011 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 05 Jun 2009 New trial record.